Want to see USAQ full AI Analyst Report?
Top Page
QHSLab
(OTC:USAQ)
Select Model
Select Model
Rating:63Neutral
Price Target:
$0.33
▲(3.13% Upside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by improving fundamentals (profitability recovery and a de-risked balance sheet) but held back by negative TTM operating/free cash flow, which raises earnings-quality and flexibility concerns. Valuation is favorable with a low P/E, while technicals are only modestly constructive (short-term improvement but still below longer-term averages). Corporate updates are positive and support the turnaround narrative.
Positive Factors
Recurring ISP platform growth
The shift toward a recurring, software-enabled healthcare platform can improve revenue visibility and deepen provider relationships. Rapid ISP growth and increasing revenue mix support a more scalable business model if adoption continues.
Negative Factors
Negative operating and free cash flow
Negative cash conversion despite reported net income weakens earnings quality and limits internally funded growth. If working-capital swings or higher cash costs persist, QHSLab may need tighter spending controls or external capital to maintain expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring ISP platform growth
The shift toward a recurring, software-enabled healthcare platform can improve revenue visibility and deepen provider relationships. Rapid ISP growth and increasing revenue mix support a more scalable business model if adoption continues.
Read all positive factors
QHSLab (USAQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.26M
Dividend YieldN/A
Average Volume (3M)3.39K
Price to Earnings (P/E)7.4
Beta (1Y)1.32
Revenue Growth24.61%
EPS GrowthN/A
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.05
Shares Outstanding15,032,788
10 Day Avg. Volume5,005
30 Day Avg. Volume3,386
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
QHSLab Business Overview & Revenue Model
Company Description
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also devel...
QHSLab Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.02M | 2.69M | 2.13M | 1.41M | 1.24M | 1.41M |
| Gross Profit | 2.02M | 1.81M | 1.36M | 793.61K | 619.52K | 670.75K |
| EBITDA | 718.32K | 785.56K | 352.39K | -91.29K | -434.60K | -487.63K |
| Net Income | 524.11K | 457.42K | -259.24K | -468.36K | -996.00K | -770.18K |
Balance Sheet | ||||||
| Total Assets | 1.93M | 2.17M | 1.80M | 1.68M | 1.96M | 2.21M |
| Cash, Cash Equivalents and Short-Term Investments | 317.39K | 636.16K | 157.17K | 51.58K | 178.69K | 286.86K |
| Total Debt | 95.55K | 20.00K | 1.72M | 1.78M | 1.68M | 1.30M |
| Total Liabilities | 375.82K | 546.08K | 2.41M | 2.06M | 1.88M | 1.38M |
| Stockholders Equity | 1.56M | 1.62M | -607.76K | -375.62K | 76.25K | 824.07K |
Cash Flow | ||||||
| Free Cash Flow | -107.43K | 178.12K | 142.44K | -159.63K | -388.11K | -509.31K |
| Operating Cash Flow | -107.43K | 178.12K | 142.44K | -159.63K | -350.99K | -354.74K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -37.12K | -154.57K |
| Financing Cash Flow | 256.46K | 300.87K | -36.85K | 32.52K | 279.95K | 701.82K |
QHSLab Technical Analysis
Positive
0.32
Price Trends
0.32
Positive
0.41
Negative
0.50
Negative
Market Momentum
<0.01
Negative
56.04
Neutral
48.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USAQ, the sentiment is Positive. The current price of 0.32 is below the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.32, and below the 200-day MA of 0.50, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.04 is Neutral, neither overbought nor oversold. The STOCH value of 48.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USAQ.
QHSLab Risk Analysis
QHSLab disclosed 43 risk factors in its most recent earnings report. QHSLab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
QHSLab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $5.26M | 7.38 | 51.21% | ― | 24.61% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.85M | >-0.01 | -605.75% | ― | 8.36% | 88.88% | |
44 Neutral | $1.29M | -0.16 | -123.09% | ― | ― | 87.54% | |
43 Neutral | $3.98M | -0.03 | -129.76% | ― | 219.17% | 90.58% |
* Healthcare Sector Average
USAQ
QHSLab
0.35
0.17
98.86%
NUWE
Nuwellis
0.78
-166.17
-99.53%
AEMD
Aethlon Medical
1.82
-31.88
-94.60%
VTAK
Catheter Precision
0.21
-2.27
-91.53%
BBLG
Bone Biologics
0.57
-1.58
-73.58%
QHSLab Corporate Events
Business Operations and StrategyFinancial Disclosures
QHSLab Reports Strong Q2 Growth in ISP Revenue
Positive
Aug 3, 2026
On August 3, 2026, QHSLab reported unaudited results for the second quarter and first half of 2026, highlighting strong growth in its Integrated Service Program revenue and a shift toward a recurring, software-enabled healthcare platform. Manageme...
Business Operations and StrategyFinancial Disclosures
QHSLab Highlights Investor Outreach at Planet MicroCap Conference
Positive
Jun 17, 2026
QHSLab, Inc. announced plans for its representatives to participate in the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub conference, scheduled for June 16-18, 2026, at the Bellagio Resort Casino in Las Vegas, Nevada. The company intends ...
Business Operations and StrategyFinancial Disclosures
QHSLab Reports Strong April Revenue Growth, Expands Q-Connect
Positive
May 26, 2026
On May 26, 2026, QHSLab reported unaudited April 2026 revenue of about $325,889, up from $207,538 a year earlier, a 57% increase tied to greater use of its digital medicine platform and integrated service program. Management highlighted a focus on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.